<p>根据 Handelsbanken Fonder AB 最近向 SEC 提交的 13F 文件，该公司在 2023 年第二季度将其在 Illumina, Inc.（NASDAQ:ILMN - 免费报告）的持股比例降低了 54.3%。该公司在此期间出售了 47,932 股后，持有 40,400 股这家生命科学公司的股票。Handelsbanken Fonder AB 在 Illumina 的持股在最近一个季度末价值为 3,855,000 美元。</p>
<ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
<p>其他一些机构投资者和对冲基金也买卖了 ILMN 的股票。Corvex Management LP 在第一季度将其在 Illumina 的持股比例增加了 125.2%。Corvex Management LP 现在拥有 3,829,608 股这家生命科学公司的股票，价值为 303,841,000 美元，此前在上个季度又购买了 2,129,449 股。AQR Capital Management LLC 在第一季度将其在 Illumina 的持股增加了 361.7%。AQR Capital Management LLC 现在拥有 2,121,585 股这家生命科学公司的股票，价值为 165,484,000 美元，此前在上个季度又购买了 1,662,093 股。Jacobs Levy Equity Management Inc.在第一季度将其在 Illumina 的持股增加了 11,714.9%。Jacobs Levy Equity Management Inc.现在拥有 1,161,882 股这家生命科学公司的股票，价值为 92,184,000 美元，此前在上个季度又收购了 1,152,048 股。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度将其在 Illumina 的持股增加了 51.7%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 现在拥有 1,960,385 股这家生命科学公司的股票，价值为 155,537,000 美元，此前在上个季度又收购了 667,978 股。最后，PGGM Investments 在第二季度将其在 Illumina 的持股增加了 115.1%。PGGM Investments 现在拥有 1,149,408 股这家生命科学公司的股票，价值为 109,665,000 美元，此前在上个季度又收购了 614,973 股。89.42% 的股票由机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>最近，一些分析师对 ILMN 股票发表了看法。Weiss Ratings 在 10 月 8 日的报告中重申了对 Illumina 股票的 “卖出（d+）” 评级。巴克莱在 10 月 31 日的研究报告中将 Illumina 的目标价从 95.00 美元上调至 100.00 美元，并给予该股票 “减持” 评级。大和资本市场在 8 月 12 日的研究报告中将 Illumina 的评级从 “跑赢大盘” 下调至 “中性”，并设定了 94.00 美元的目标价。瑞银集团在 10 月 31 日的报告中将 Illumina 的目标价从 110.00 美元上调至 120.00 美元，并给予该股票 “中性” 评级。最后，Cowen 在 10 月 31 日的研究报告中重申了对 Illumina 股票的 “持有” 评级。五位研究分析师对该股票给予了买入评级，十二位给予了持有评级，三位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 115.00 美元。</p>
<ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
<p><strong>查看我们关于 Illumina 的最新报告</strong></p>
<h2>Illumina 股价上涨 1.7%</h2>
<p>NASDAQ ILMN 的股票在周二开盘时为 125.96 美元。Illumina, Inc.的 12 个月最低价为 68.70 美元，最高价为 153.06 美元。该公司的市值为 192.5 亿美元，市盈率为 15.94，市盈增长比率为 2.34，贝塔值为 1.42。该公司的 50 日简单移动平均线为 105.72 美元，200 日简单移动平均线为 98.01 美元。公司的速动比率为 1.41，流动比率为 1.81，债务与股本比率为 0.66。</p>
<ul>
<li>Palantir 未能进入标准普尔 500 指数；它仍然看起来像是一个买入机会</li>
</ul>
<p>Illumina（NASDAQ:ILMN - 获取免费报告）最近在 10 月 30 日宣布了其季度财报。这家生命科学公司报告的每股收益为 1.34 美元，超出市场共识预期的 1.16 美元，超出 0.18 美元。该公司在本季度的收入为 10.8 亿美元，而分析师预期为 10.7 亿美元。Illumina 的净利润率为 29.36%，股本回报率为 28.93%。与去年同期相比，该公司的收入增长了 0.4%。在去年同期，该公司每股收益为 1.14 美元。Illumina 已将其 2025 财年的指导目标设定为 4.650-4.750 每股收益。分析师预计 Illumina, Inc.在当前财年将发布 4.51 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 Illumina 新闻中，董事 Scott Gottlieb 在 11 月 3 日的交易中购买了 500 股该公司的股票。该股票的平均购买成本为每股 122.13 美元，总交易额为 61,065.00 美元。购买后，该董事在公司中持有 12,523 股，价值约为 1,529,433.99 美元。此次交易使其持股增加了 4.16%。该购买在向证券交易委员会的法律文件中披露，可以通过此超链接访问。内部人士持有公司 2.60% 的股票。</p>
<h2>Illumina 公司简介</h2>
<p>（免费报告）</p>
<p>Illumina, Inc.在美国、新加坡、英国及国际市场提供基于测序和阵列的遗传和基因组分析解决方案。它通过核心 Illumina 和 GRAIL 两个部门运营。该公司提供测序和阵列基础的仪器和耗材，包括试剂、流动池和文库准备；全基因组测序套件，能够测序各种规模和复杂度的整个基因组；以及靶向重测序套件，能够测序外显子、特定基因和 RNA 或其他感兴趣的基因组区域。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Illumina</li>
<li>如何利用分析师评级进行交易</li>
<li>D-Wave：是时候买入了吗？还是下跌才刚刚开始？</li>
<li>如何选择高评级股票</li>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>零售财报汇总：沃尔玛表现出色，塔吉特在第三季度下滑</li>
</ul>
<p><strong>想看看其他对 ILMN 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取 Illumina, Inc.（NASDAQ:ILMN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Illumina 吗？</h2>
<p>在考虑 Illumina 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Illumina 并不在名单上。</p>
<p>虽然 Illumina 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ILMN

<p>Handelsbanken Fonder AB 在第二季度减少了对 Illumina, Inc. 的持股，减持幅度为 54.3%，出售了 47,932 股。Illumina 的股票分析师评级不一，目前的平均评级为 “持有”，目标价格为 115.00 美元。该股票开盘价为 125.96 美元，12 个月的价格区间为 68.70 美元至 153.06 美元。Illumina 报告第三季度每股收益为 1.34 美元，超出预期</p>

<p>Handelsbanken Fonder AB lowered its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 40,400 shares of the life sciences company's stock after selling 47,932 shares during the period. Handelsbanken Fonder AB's holdings in Illumina were worth $3,855,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Handelsbanken Fonder AB 最近向 SEC 提交的 13F 文件，该公司在 2023 年第二季度将其在 Illumina, Inc.（NASDAQ:ILMN - 免费报告）的持股比例降低了 54.3%。该公司在此期间出售了 47,932 股后，持有 40,400 股这家生命科学公司的股票。Handelsbanken Fonder AB 在 Illumina 的持股在最近一个季度末价值为 3,855,000 美元。</p>
</div><ul>
<li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li>
</ul>
<div class="lb-trans"><ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Corvex Management LP grew its position in shares of Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock valued at $303,841,000 after purchasing an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC grew its holdings in Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company's stock valued at $165,484,000 after buying an additional 1,662,093 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company's stock worth $92,184,000 after acquiring an additional 1,152,048 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Illumina by 51.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company's stock worth $155,537,000 after acquiring an additional 667,978 shares in the last quarter. Finally, PGGM Investments raised its holdings in shares of Illumina by 115.1% during the 2nd quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company's stock worth $109,665,000 after acquiring an additional 614,973 shares in the last quarter. 89.42% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金也买卖了 ILMN 的股票。Corvex Management LP 在第一季度将其在 Illumina 的持股比例增加了 125.2%。Corvex Management LP 现在拥有 3,829,608 股这家生命科学公司的股票，价值为 303,841,000 美元，此前在上个季度又购买了 2,129,449 股。AQR Capital Management LLC 在第一季度将其在 Illumina 的持股增加了 361.7%。AQR Capital Management LLC 现在拥有 2,121,585 股这家生命科学公司的股票，价值为 165,484,000 美元，此前在上个季度又购买了 1,662,093 股。Jacobs Levy Equity Management Inc.在第一季度将其在 Illumina 的持股增加了 11,714.9%。Jacobs Levy Equity Management Inc.现在拥有 1,161,882 股这家生命科学公司的股票，价值为 92,184,000 美元，此前在上个季度又收购了 1,152,048 股。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度将其在 Illumina 的持股增加了 51.7%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 现在拥有 1,960,385 股这家生命科学公司的股票，价值为 155,537,000 美元，此前在上个季度又收购了 667,978 股。最后，PGGM Investments 在第二季度将其在 Illumina 的持股增加了 115.1%。PGGM Investments 现在拥有 1,149,408 股这家生命科学公司的股票，价值为 109,665,000 美元，此前在上个季度又收购了 614,973 股。89.42% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts have recently weighed in on ILMN shares. Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Illumina in a report on Wednesday, October 8th. Barclays boosted their price objective on Illumina from $95.00 to $100.00 and gave the stock an &#34;underweight&#34; rating in a research note on Friday, October 31st. Daiwa Capital Markets lowered Illumina from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $94.00 price objective for the company. in a research note on Tuesday, August 12th. UBS Group lifted their target price on Illumina from $110.00 to $120.00 and gave the stock a &#34;neutral&#34; rating in a report on Friday, October 31st. Finally, Cowen reissued a &#34;hold&#34; rating on shares of Illumina in a research report on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $115.00.</p>
<div class="lb-trans"><p>最近，一些分析师对 ILMN 股票发表了看法。Weiss Ratings 在 10 月 8 日的报告中重申了对 Illumina 股票的 “卖出（d+）” 评级。巴克莱在 10 月 31 日的研究报告中将 Illumina 的目标价从 95.00 美元上调至 100.00 美元，并给予该股票 “减持” 评级。大和资本市场在 8 月 12 日的研究报告中将 Illumina 的评级从 “跑赢大盘” 下调至 “中性”，并设定了 94.00 美元的目标价。瑞银集团在 10 月 31 日的报告中将 Illumina 的目标价从 110.00 美元上调至 120.00 美元，并给予该股票 “中性” 评级。最后，Cowen 在 10 月 31 日的研究报告中重申了对 Illumina 股票的 “持有” 评级。五位研究分析师对该股票给予了买入评级，十二位给予了持有评级，三位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 115.00 美元。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p><strong>View Our Latest Report on Illumina</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Illumina 的最新报告</strong></p>
</div><h2>Illumina Trading Up 1.7%</h2>
<div class="lb-trans"><h2>Illumina 股价上涨 1.7%</h2>
</div><p>Shares of NASDAQ ILMN opened at $125.96 on Tuesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The firm has a market cap of $19.25 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The business has a fifty day simple moving average of $105.72 and a two-hundred day simple moving average of $98.01. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.</p>
<div class="lb-trans"><p>NASDAQ ILMN 的股票在周二开盘时为 125.96 美元。Illumina, Inc.的 12 个月最低价为 68.70 美元，最高价为 153.06 美元。该公司的市值为 192.5 亿美元，市盈率为 15.94，市盈增长比率为 2.34，贝塔值为 1.42。该公司的 50 日简单移动平均线为 105.72 美元，200 日简单移动平均线为 98.01 美元。公司的速动比率为 1.41，流动比率为 1.81，债务与股本比率为 0.66。</p>
</div><ul>
<li>Palantir Was Left Out of the S&amp;P 500; It Still Looks Like a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Palantir 未能进入标准普尔 500 指数；它仍然看起来像是一个买入机会</li>
</ul>
</div><p>Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company's revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Illumina（NASDAQ:ILMN - 获取免费报告）最近在 10 月 30 日宣布了其季度财报。这家生命科学公司报告的每股收益为 1.34 美元，超出市场共识预期的 1.16 美元，超出 0.18 美元。该公司在本季度的收入为 10.8 亿美元，而分析师预期为 10.7 亿美元。Illumina 的净利润率为 29.36%，股本回报率为 28.93%。与去年同期相比，该公司的收入增长了 0.4%。在去年同期，该公司每股收益为 1.14 美元。Illumina 已将其 2025 财年的指导目标设定为 4.650-4.750 每股收益。分析师预计 Illumina, Inc.在当前财年将发布 4.51 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Illumina news, Director Scott Gottlieb acquired 500 shares of the firm's stock in a transaction on Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 2.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Illumina 新闻中，董事 Scott Gottlieb 在 11 月 3 日的交易中购买了 500 股该公司的股票。该股票的平均购买成本为每股 122.13 美元，总交易额为 61,065.00 美元。购买后，该董事在公司中持有 12,523 股，价值约为 1,529,433.99 美元。此次交易使其持股增加了 4.16%。该购买在向证券交易委员会的法律文件中披露，可以通过此超链接访问。内部人士持有公司 2.60% 的股票。</p>
</div><h2>Illumina Company Profile</h2>
<div class="lb-trans"><h2>Illumina 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.</p>
<div class="lb-trans"><p>Illumina, Inc.在美国、新加坡、英国及国际市场提供基于测序和阵列的遗传和基因组分析解决方案。它通过核心 Illumina 和 GRAIL 两个部门运营。该公司提供测序和阵列基础的仪器和耗材，包括试剂、流动池和文库准备；全基因组测序套件，能够测序各种规模和复杂度的整个基因组；以及靶向重测序套件，能够测序外显子、特定基因和 RNA 或其他感兴趣的基因组区域。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Illumina</li>
<li>How to trade using analyst ratings</li>
<li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li>
<li>How to Choose Top Rated Stocks</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Illumina</li>
<li>如何利用分析师评级进行交易</li>
<li>D-Wave：是时候买入了吗？还是下跌才刚刚开始？</li>
<li>如何选择高评级股票</li>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>零售财报汇总：沃尔玛表现出色，塔吉特在第三季度下滑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ILMN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ILMN 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取 Illumina, Inc.（NASDAQ:ILMN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ILMN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Illumina Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Illumina 吗？</h2>
</div><p>Before you consider Illumina, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Illumina 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Illumina 并不在名单上。</p>
</div><p>While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Illumina 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Handelsbanken Fonder AB 出售了 47,932 股 Illumina 公司（股票代码：ILMN）的股票